Opinion|Videos|March 18, 2024
Current Front-Line Targeted Treatments in Ph+ ALL
Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Advertisement
Episodes in this series
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Prior Authorization Ranked Top Barrier to Health Care Access After Cost
2
FDA Flags Administration Concerns for Aquestive's Noninvasive Epinephrine Film
3
Contributor: The Majority (57.5%) of Commercially Insured Patients Had 1 or More Chronic Conditions in 2024
4
Pulmonary Fibrosis and Sexual Health: A Q&A With Na’ama Avitzur, MD
5
